Abstract: In Mongolia, flu and flu-like diseases affect many people, and pneumonia is a public health concern. Therefore, we have an urgent need to research and develop a new medicinal syrup to replace imported products using raw materials grown in Mongolia and to compare it with similar products. There are imported cough syrup products on the pharmaceutical market of Mongolia, but there are domestic pharmaceutical products. Moreover, there is limited research data on cough relief. The main goal of the research team is to compare the experimentally obtained syrup containing Plantago asiatica L, Malva Sylvestris L. and syrup containing Plantago major L. Juice, honey that produced by Monos Pharm LLC whish the cough relieving drug Gerbion syrup. Material and methods: The vivarium of the pharmacology laboratory, Drug research institute, TPC7062Ti mark IVC system (Shanghai Pretty Industries Co.,Ltd, China) in a special environment with one care and one feeding regimen (Lab Mice Diet, Constant Formula Balanced Nutrition, Jiangsu Xietong Pharmaceutical Bio- Engineering Co., LTD, China, www.jsxtsw.com ) used 64 non-WISTAR white rats weighing 180-218 g. Experimental rats were smoked with an aerosol of 17% citric acid aqueous solution for 5 minutes. The statistical processing of the research results was done using the One-Way ANOVA/Multiple comparisons data of the GraphPad Prism 8 program. Results and conclusion Expressing the number of coughs produced in the experimental rats as a percentage (%), the control group showed 3.95% cough relief, and the experimental group-1 by 48.4%, experimental group-2 by 71.1%, comparison group by 74.6%, respectively has reduced. Experimental group -2 and comparison group for dry cough caused by citric acid 17%, it affects the cough receptors in the mucous membrane of the respiratory tract and relaxes the bronchial muscles (A and C fiber).

Background: Obesity, especially central obesity, is a risk factor for non-communicable chronic diseases such as dyslipidemia, type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD), and metabolic syndrome (MetS). Aim: Study the association between the subcutaneous fat area (SFA) and visceral fat area (VFA) with lipid metabolism parameters in adults with MetS. Materials and Methods: Data from 1511 participants who visited the ‘NURA Mongolia’ Ai Health screening center between September 2023 and February 2024, including general information, DEXA (Dual X-ray Absorptiometry), and biochemical analysis results, were used. Metabolic syndrome (MeS) was assessed based on the harmonizing criteria 2009 (≥3 criteria). VFA and SFA were categorized into four groups using quartiles (Q1-Q4). Statistical analysis was performed using SPSS v26, including T-tests, multiple logistic regression (OR, 95% CI), and ROC (AUC) analysis. Results: The average age of the participants was 30.5±3.9 years, with a BMI of 25.1 kg/m², and 49.5% were male. The group with MetS (n=531) had significantly higher levels of VFA and SFA compared to the group that rated their health as relatively healthy and had no clinical diagnosis (n=979) (control group) (p<0.0001), with males showing higher VFA and females showing higher SFA (p<0.0001). The Q4 group for VFA had a significant association with MetS in males (4.611, 95% CI=2.394–9.591) and females (2.253, 95% CI=1.097-3.912) (p<0.001). Logistic regression analysis showed that increased VFA was more strongly associated with MetS in males (β=0.325, p<0.0001) and females (β=0.338, p<0.003) than BMI. The AUC for predicting MetS was 0.790 (95% CI=0.750-0.831) for VFA and 0.401 (95% CI=0.351-0.451) for SFA, with all results being statistically significant (p<0.001). VFA had a higher predictive value compared to other markers. Conclusion In healthy men with metabolic syndrome, VFA is more prominently defined, while SFA is higher in healthy women. Since VFA is a better predictor of metabolic syndrome than SFA, it increases the risk of diseases such as cardiovascular diseases and type 2 diabetes in men, whereas SFA in women serves as a protective factor.